HRS Comments – AHRQ Report on the Use of CRT (July 2019)

July 24, 2019 – The Heart Rhythm Society submitted a letter in response to the Agency for Healthcare Research and Quality (AHRQ)’s draft Technology Assessment Report regarding the use of CRT, which was released on June 20 2019.

On June 20, 2019 the Agency for Healthcare Research and Quality released the updated draft of its Technology Assessment regarding the use of Cardiac Resynchronization Therapy, which reassess the effectiveness and harms of cardiac resynchronization therapy with (CRT-D) and without defibrillator (CRT-P) in patients with an left ventricle ejection fraction ≤35% and a QRS duration ≥120 ms, the effectiveness and harms of alternative cardiac resynchronization therapy techniques in the same patient population, and cardiac resynchronization therapy or His bundle pacing in patients with an left ventricle ejection fraction between 36% and 50% and atrioventricular block.

On July 24, 2019, the Heart Rhythm Society, in collaboration with the American College of Cardiology and the Heart Failure Society of America, submitted comments in response to the draft Technology Assessment.